rifaximin
Selected indexed studies
- Review of rifaximin as treatment for SIBO and IBS. (Expert Opin Investig Drugs, 2009) [PMID:19243285]
- Rifaximin treatment in hepatic encephalopathy. (N Engl J Med, 2010) [PMID:20335583]
- Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis. (PLoS One, 2022) [PMID:35471992]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Review of rifaximin as treatment for SIBO and IBS. (2009) pubmed
- Rifaximin treatment in hepatic encephalopathy. (2010) pubmed
- Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis. (2022) pubmed
- Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat. (2021) pubmed
- Rifaximin and alternative agents in the management of irritable bowel syndrome: A comprehensive review. (2024) pubmed
- Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis. (2021) pubmed
- Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence. (2024) pubmed
- Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. (2022) pubmed
- The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial. (2021) pubmed
- Therapeutic potential of rifaximin in liver diseases. (2024) pubmed